Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Am J Kidney Dis. 2012 Aug 22;61(1):44–56. doi: 10.1053/j.ajkd.2012.07.014

Figure 4.

Figure 4

Meta-regression analyses examining the association of total-study-period ESA dose (per epoetin alfa–equivalent 10,000 U/wk increment) with the secondary outcomes [4A, unadjusted; 4B, adjusted for target hemoglobin; and 4C, adjusted for mortality rate (expressed per 1000 person-years) in the control group]. The incidence rate ratio (IRR) and 95% confidence interval (CI) is displayed on a logarithmic scale. ESRD denotes end-stage renal disease.